Small Molecules
17 September 2014
Denovo Biopharma Acquires Late-Stage Oncology Drug From lilly For Development As A Personalized Medicine17 September 2014
Cardioxyl Presents Oral Heart Failure Treatment Data For Its Experimental HNO Prodrug At HFSA 18th Annual Scientific Meeting17 September 2014
Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma17 September 2014
FDA Approves MOVANTIK™ (naloxegol) Tablets For The Treatment Of Opioid-Induced Constipation In Adult Patients With Chronic Non-Cancer Pain16 September 2014
UCERIS® (budesonide) 2mg Rectal Foam for the Induction of Remission of Mild-to-Moderate Distal Ulcerative Colitis Granted Tentative Approval by FDA16 September 2014
Merck Announces Data from Pivotal Phase 3 Fracture Outcomes Study for Odanacatib, an Investigational Oral, Once-Weekly Treatment for Osteoporosis16 September 2014
Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer15 September 2014
Avanir Pharmaceuticals Announces Positive Phase II Trial Results for AVP-923 in Treatment of Agitation in Patients with Alzheimer’s Disease15 September 2014
Alios BioPharma Presents Data on Its Anti-HCV Nucleotide AL-335 at Special Conference on Hepatitis C15 September 2014
Amgen Presents Analyses Of Phase 3 Ivabradine Data For The Treatment Of Chronic Heart Failure12 September 2014
to-BBB Announces Positive Data from Phase 1 Clinical Study12 September 2014
Teva Presents New Clinical Safety Data in RRMS Patients Treated with Laquinimod for Two or More Years at Joint ACTRIMS-ECTRIMS Meeting12 September 2014
Oxygen Biotherapeutics Announces Halt of Oxycyte Phase IIb Traumatic Brain Injury Trial12 September 2014
New data confirm high efficacy of Gilenya® in achieving ‘no evidence of disease activity (NEDA)’ based on four key measures of MS11 September 2014
New Data from ENDORSE Show Positive Results Continued over Five Years with TECFIDERA® (Dimethyl Fumarate) in a Wide Range of Multiple Sclerosis Patients11 September 2014
Takeda and Orexigen Announce FDA Approval of Contrave® (naltrexone HCI and bupropion HCI) Extended-release Tablets for Chronic Weight Management11 September 2014
G1 Therapeutics Initiates Phase 1 Clinical Trial of G1T28-111 September 2014
U.S. FDA Approves New Indication for the Use of XTANDI® (enzalutamide) Capsules for Patients with Metastatic Castration-Resistant Prostate Cancer11 September 2014
Clovis Oncology Announces First Patient Enrolled in Lucitanib Phase 2 Study in FGF-aberrant Advanced Breast Cancer10 September 2014
Enanta Pharmaceuticals Announces the Initiation of Phase 2b Clinical Trial with Regimen Containing HCV Protease Inhibitor ABT-49310 September 2014
FDA Advisory Committee Recommends Against Approval of Actavis’ Nebivolol/Valsartan Fixed-Dose Combination NDA for Treatment of HypertensionNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports